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I 
ZUSAMMENFASSUNG 
 
Die Mehrzahl der im Thymus generierten CD4+CD25high regulatorischen T-Zellen (Treg) 
besitzt hohe Affinität gegenüber körpereigenen Antigenen. Es ist bekannt, dass T-Zell 
Rezeptoren (TCR) auf Treg Zellen in der Peripherie zusätzlich auch fremde Antigene 
verschiedener Pathogene wie Parasiten, Bakterien und Viren erkennen. 
Wenig ist bekannt über das klonale T-Zell Rezeptor Repertoire dieser Treg Populationen und 
ihre Beziehung zu CD4+CD25low effektor T-Zellen (Teff) im Menschen. In dieser Studie 
analysieren wir humane TCR auf expandierten Treg and Teff Zellen mit definierter Antigen 
Spezifität für Haupthistokompatibilitätskomplex (MHC) Klasse II restringierte „fremde“ 
Epitope des Cytomegalovirus (CMV).  
Bemerkenswerterweise fanden wir, dass der gleiche TCR Vβ-CDR3 Klon in beiden 
funktionell unterschiedlichen Subpopulationen in vitro dominant expandiert ist. 
Im Unterschied zu ihren klonal-identischen Teff Gegenspielern, exprimieren die suppressiven 
Treg Zellen kaum CD127 und IL-2, aber hohe Mengen an IFNγ und IL-10. Zusammen mit der 
signifikant erhöhten FOXP3 Expression, trotz unvollständiger foxp3-DNA Demethylierung, 
lassen sich die CMV-spezifischen CD4+CD25high Treg Zellen einem induzierten Treg 
(iTreg) Phänotyp zuordnen mit Ähnlichkeit zum beschriebenen Tr-1 Phänotyp. 
Darüber hinaus konnten wir die klonale TCR Identität auch in frisch isolierten CD4+CD25low 
und CD4+CD25high Subpopulationen bestätigen, was die Entstehung von CMV-spezifischen 
Treg Zellen bereits in vivo nahe legt. Periphere CD25high Treg Zellen supprimieren die anti-
virale Immunantwort in Patienten mit häufigen CMV-Reaktivierungen, was auf ihre Bildung 
als Reaktion chronischer Antigenexposition interpretiert werden kann. 
Unsere Ergebnisse beweisen erstmals direkt, dass aus dem gleichen humanen T-Zell Klon 
Teff und Treg Zellen mit identischer Spezifität entstehen können und lassen vermuten, dass 
die Treg Induktion in der Peripherie durch häufige Antigenexposition vorangetrieben wird.  
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SUMMARY 
 
The majority of thymically arised regulatory CD4+CD25high T cells (Treg) show high affinity 
to self-antigens. It has been proposed that T-cell receptors (TCR) on Treg cells in the 
periphery also recognize foreign-antigens from pathogens, such as bacteria and viruses. 
Studies in mice have shown that peripheral Treg cells can be generated not only from naïve 
T cells but also from effector T cells (Teff). 
However, in humans the clonal TCR-repertoire of these Treg populations and their relation to 
effector CD4+CD25low Teff is not sufficiently known up to date. Here, we analyzed human 
TCRs derived from expanded Treg and Teff cells with defined specificity to MHC class-II 
restricted “foreign” epitopes of Cytomegalovirus (CMV).  
Remarkably, we found that both functionally distinct subsets share the same dominant TCR-
CDR3 clones in vitro. In contrast to their Teff counterparts, the Treg cells express low CD127 
and IL-2, but high IL-10 upon antigen stimulation. Therefore, together with increased FOXP3 
expression, but incomplete foxp3 DNA-demethylation, human CMV-antigen specific Treg 
cells exhibit an induced phenotype (iTreg) in vitro with similarity to recently described Tr-1 
phenotype. 
Moreover, the clonal identity was confirmed in freshly isolated CD4+CD25low and 
CD4+CD25high subsets, suggesting their generation occurred already in vivo. Peripheral 
CD25high Treg cells suppress the anti-viral immune response in patients with frequent CMV-
reactivations, implying their development as reaction on chronic antigen-exposure. 
Our results demonstrate directly for the first time, that the same human T-cell clone can 
possess the phenotype of Teff and Treg cells with specificity to identical foreign epitopes and 
suggest that Treg-induction in the periphery is supported by frequent antigen-exposure. 
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1 INTRODUCTION 
 
1.1 ORIGIN OF HUMAN REGULATORY T CELLS 
 
Human regulatory CD4+CD25high T cells (Treg) play a crucial role in preventing 
autoimmunity, but they can also weaken the organism`s immune response to infection 
(Shevach, 2002) (Thompson and Powrie, 2004) (Powrie, et al., 2003). Treg cells arise from 
two major sources; immature T cells committed to the lineage of natural Treg cells (nTreg) in 
the thymus and mature T cells recruited by antigenic induction to the regulatory population in 
the periphery (iTreg) (Sakaguchi and Powrie, 2007).  
 
 
1.2 RELATIONSHIP OF TEFF AND Treg CELLS 
 
Studies in mice and humans have shown that (Larkin, et al., 2008) peripheral Treg 
cells can be generated not only from naïve CD4+ cells (Apostolou and von Boehmer, 2004) 
but also from CD4+CD25- effector T cells upon suboptimal activation of autoantigens 
(Knoechel, et al., 2005) (Seddon and Mason, 1999) or foreign antigens (Curotto de Lafaille, 
et al., 2004) (Kretschmer, et al., 2005) (Vukmanovic-Stejic, et al., 2006).  
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1.3 ANTIGEN SPECIFICITIY OF Treg CELLS IN INFECTION 
  
 Recently, several groups reported elevated percentages of CD4+CD25+ Treg cells in 
the total T-cell population isolated from peripheral blood of patients undergoing diverse 
chronic infections of microbes (Belkaid and Rouse, 2005), parasites (Suffia, et al., 2006) and 
viruses, such as Herpes simplex virus (Suvas, et al., 2003), Hepatitis C Virus (Boettler, et al., 
2005) (Rushbrook, et al., 2005) and Cytomegalovirus (Vukmanovic-Stejic, et al., 2006).  
Mostly, the role of human Treg cells in response to infections has been examined by in vitro 
suppression assays. One study reports that during chronic Hepatitis C Virus (HCV) infection, 
cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific 
CD8+ T cells (Boettler, et al., 2005). Importantly, CD4+CD25+ T cells from person recovered 
HCV infection and from healthy blood donors exhibited significant less suppressive activity. 
This was associated with a higher frequency of circulating CD4+CD25+ T cells.  
Of particular interest was the finding that the suppression, mediated by the freshly isolated 
polyclonal CD4+CD25+ Treg cells, was not restricted to HCV-specific CD8+ T cells but also 
to Influenza virus specific CD8+ T cells. 
Although, this experiment and other studies (Boettler, et al., 2005) (Belkaid and Rouse, 
2005) clearly verify the ability of human CD4+CD25+ Treg cells to down-modulate T-effector 
responses specific for exogenous antigens, it is still unclear whether the Treg antigen-
recognition is specific or rely on inherent cross-reactivity and bystander effect (Larkin, et al., 
2008) (Ochando, et al., 2005). 
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1.4 T-CELL RECEPTOR (TCR) REPERTOIRE OF Treg CELLS 
   
 Some studies conclude that Treg cells express a diverse repertoire of TCRs that 
overlap with the TCR repertoire of CD4+ naïve T cells or CD4+CD25- memory T cells 
(Kasow, et al., 2004) (Taams, et al., 2002) (Fujishima, et al., 2005), whereas other studies in 
mice conclude that peripheral Treg cells express different TCRs that are usually self-reactive 
and intersect with TCR expressed by thymic-derived Treg cells (Hsieh, et al., 2006). 
Moreover, a recently published report in mice has shown that thymically arised Foxp3+ Treg 
recognize foreign antigenic peptides as often as non-regulatory T cells (Pacholczyk, et al., 
2007). 
So far, analysis of human T-cell receptors (TCR) expressed on peripheral CD4+CD25+ Treg 
cells reached no uniform conclusion. 
 
 
1.5 PHENOTYPIC MARKERS OF HUMAN CD4+ Treg CELLS 
  
 Although, the expression of CD25 (the γ-chain of high-affinity IL-2 receptor) on T cells 
can be a useful marker of Treg cells on peripheral blood cells, its expression is not 
necessarily associated with Treg cell function as it is also expressed by activated non-
regulatory effector T cells. Therefore, in freshly isloated antigen non-exposured PBMCs 
CD4+CD25high Treg cells are distingushed in many current studies from CD25low – 
CD25intermediate efftector T-cell populations. Other molecules, including the glucocoritcoid-
induced TNFR family related gene (GITR) and the cytotoxic T-lymphocyte antigen-4 (CTLA-
4) have been used as markers. However, both are activation markers also expressed on 
activated effector lymphocytes. More recently, two groups found that CD127 expression (the 
α chain of the interleukin-7 receptor) inversely correlates with suppressive function of CD4+ 
Treg cells (Seddiki, et al., 2006) (Liu, et al., 2006). 
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The transcription factor Foxp3 (Forkhead box P3) is currently considered to be the most 
reliable marker for CD4+ Treg cells in mice and men. Although, human FOXP3 expression is 
not as restricted to Treg cells as the murine counterpart, because it is also expressed in 
effector T cells at a relatively low level. A notable difference between humans and mice is 
that FOXP3 expression in human CD4+ T cells is tightly linked to TCR-mediated activation 
(Roncarolo and Gregori, 2008). Recent studies further revealed, that human nTreg cells 
express FOXP3 stable, whilst induced Treg cells assemble transient upregulation. These 
CD4+CD25high Treg cells are induced in the periphery by MHC-peptide stimulation, secrete 
low levels of IL-2, in some studies TGF-β and/or IFNγ and high levels of IL-10 (T-regulatory 
cells type-1, Tr-1) (Roncarolo and Gregori, 2008). 
 
 
1.6 FOXP3 IN HUMAN ANTIGEN INDUCED Treg CELLS 
  
 Foxp3 expression has been proposed to determine the fate of thymic precursors to 
the natural Treg-cell lineage (Fontenot, et al., 2005) and to be a crucial master transcription 
factor in the induction of peripheral Treg-cell populations (Apostolou and von Boehmer, 
2004) (Hori and Sakaguchi, 2004). Conversely, in humans not all CD4+ FOXP3- T cells that 
are induced to express FOXP3 also acquire regulatory function (Gavin, et al., 2006) (Allan, et 
al., 2008; Allan, et al., 2007), and further some but not all of the induced Treg cells that 
obtained suppressive function also expressed stable FOXP3 (Levings, et al., 2005) 
(Roncarolo, et al., 2006) (Roncarolo and Gregori, 2008) (Allan, et al., 2008).  
Recently, a conserved region within the locus of foxp3 has been identified comprising 
complete demethylation of CpG motifs in freshly isolated CD4+CD25+ Foxp3+ Treg cells but 
not in naïve CD4+CD25- T cells (Floess, et al., 2007). In contrast to these natural Treg cells, 
peripheral Tregs in mice and humans induced in vitro by TGF-β display incomplete 
demethylation despite high Foxp3 expression.  
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Additionally, these in vitro induced Tregs loose Foxp3 expression and correspondingly 
suppressive activity upon further restimulation in absence of TGF-β (Floess, et al., 2007) 
(Polansky, et al., 2008) (Baron, et al., 2007). However, whether human peripheral antigen-
induced Tregs need epigenetic modification of the foxp3 locus for lineage stability and 
suppressive function has thus far not been investigated. Recent studies on human IL-10+ 
Tr1-like Treg cells suggest unstable FOXP3 expression (Roncarolo and Gregori, 2008). 
 
 
1.7 Treg CELLS IN CHRONIC CYTOMEGALOVIRUS  INFECTION 
  
 Cytomegalovirus (CMV) infection is a major clinical problem in immunosuppressed 
patients, particularly in organ transplant recipients. About 65 % of adults are CMV 
seropositive, and T cells play a central role in controlling the persistent virus. Some 
transplant patients repeatedly suffer from active infection that can result in CMV disease and 
graft injury (Reinke, et al., 1999). In these patients the frequent crosstalk between CMV and 
T cells might favour the generation of iTreg. Notably, to date this putative coherency has not 
been investigated. 
 
 
1.8 IMPACT OF Treg CELLS ON ANTI-VIRAL T-CELL THERAPY 
  
 In contrast to the importance of viral-induced Treg cells in preventing overwhelming 
inflammatory effector T-cell response, their presence in chronic infected person might 
diminish an effective viral clearance and could explain, at least in part, why current clinical 
trials using viral-peptides, induce only weak or transient immune response or fail to produce 
therapeutic benefit. 
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In haematopoietic stem cell transplantation (HSCT) adoptive immunotherapy with allogeneic 
donor-derived T cells directed against e.g. Epstein-Barr virus (EBV) has been proven to 
prevent EBV-related lymphoma and treat the clinical manifestation of the virus (Rooney, et 
al., 1998). In solid organ transplantation (SOT) a recent approach in field of adoptive anti-
viral therapy is the generation of autologous T-cell lines, directly isolated and expanded from 
peripheral blood of the immunosuppresed organ transplant recipient, suffering from the viral 
disease. Recently, in cooperation with Savoldo et al. we published a multicenter study in 
which SOT recipients at high risk for EBV-associated post-transplantation lymphoproliferative 
disease (PTLD) were treated with autologous EBV-specific cytotoxic T lymphocytes (CTLs) 
(Savoldo, et al., 2006). Thereby, we have investigated the in vivo safety, efficacy, and 
persistence of the infused autologous EBV-CTLs. None of the treated patients developed 
PTLD. However, despite the monitored transient increase in plasma EBV-DNA after T-cell 
infusion suggestive of lysis of EBV-infected cells, there was no consistent decrease in virus 
load in peripheral-blood mononuclear cells (50% relapse). Further, returned the initial 
increase in the frequency of EBV-responsive T cells, detected by IFNγ enzyme-linked 
immunospot assays, to preinfusion levels after 2 to 6 months.  
In summary, these data are consistent with an expansion and persistence of adoptively 
transferred EBV-CTLs, but with limited long-term efficacy in the presence of continued 
immunosuppression and active chronic viral infection. We just started to introduce this 
promising therapy option also for SOT patients suffering from chronic CMV disease. Using 
adoptive T-cell therapy we presume that targeting the presence of regulatory T-cell, their 
development, clonal identity and antigen-specificity might be of main interest to improve the 
in vitro and in vivo efficacy of viral-specific T-cell lines. 
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1.9 MAIN SUBJECTS OF THE STUDY 
  
 To investigate foreign-antigen specific iTreg in humans, we used the immunologically 
well-characterized CMV in vivo “infection model”. We determined CD4+ T-cell response to 
CMV immediate-early protein 1 (IE1) and phosphoprotein 65 (pp65) epitopes by using our 
recently established method, employing protein-spanning overlapping peptide pools and 
matrix-analysis methodology (Kern, et al., 2000; Kern, et al., 1998). Individual epitope-
specific CD4+ T cells were selected, expanded, and functionally characterized according to 
their subsets expressing low or high CD25 levels, respectively.  
 
The following questions were addressed: 
1. Are T cells with regulatory properties detectable among CMV-specific T-cell lines? 
2. What are the phenotypes and functional characteristics of Treg cells specific for CMV? 
3. Are Treg and Teff cells with specificity for CMV clonally related? 
4. Are CMV-specific Treg cells detectable before in vitro expansion? 
5. Is there a correlation between chronic CMV and Treg frequency and function in vivo? 
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2 RESULTS 
 
2.1 SUBSETS OF CMV-SPECIFIC CD4+ T-CELL LINES 
  
 To isolate human CMV antigen-specific CD4+ T-cell subsets, we firstly mapped 
(Kern, et al., 1998) various seropositive donors regarding their CD4-epitope response to the 
immunodominant CMV antigens, IE1 and pp65. This had led to successful identification of 
several viral epitopes recognized by CD4+ T cells (Table 1). 
 
Tab. 1: CD4-Epitopes. 
Antigen First AA 
Sequence 
(≥15AA) Last AA 
Potential 
HLA-Restriction 
IE1 89 IKVRVDMVRHRIKEHMLKK 107 DR13 
IE1 269 LTHIDHIFMDILTTCVETM 288 DR3 
pp65 25 AVFSRGDTPVLPHET 39 DR3 
pp65 45 LLQTGHIVRVSQPSL 59 DR13, DR15 
pp65 245 TLGSDVEEDLTMTRNPQPF 263 DR3 
AA: amino acid; HLA: Human leukocyte antigen; IE1: Immediate early protein 1; pp65: 
Phospho-protein 65 of Cytomegalovirus. 
 
 
Secondly, we isolated cells responding to these CD4-epitopes (0.2–0.5 %) from PBMC by 
IFNγ secretion assay (Hammer, et al., 2005). Specific T cells were expanded in vitro in the 
presence of irradiated autologous PBMC over 14 days (Figure 1A) to cell numbers of 0.5-1.0 
x108 CD3+ T cells, and as expected predominantly consisted of CD4+ T cells.  
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Figure 1A. Isolation and Expansion Protocol of CMV Epitope-Specific T Cells 
PBMC from CMV seropositive donors are short-term stimulated with peptides coding for 
identified CD4-epitopes on the CMV antigens (Ag) pp65 and IE1. Specifically isolated cells 
are subsequently expanded in the presence of peptide-loaded APC and rIL-2 over 14 days. 
 
Re-stimulation of expanded T cells with autologous antigen presenting cells (APC) and the 
specific antigen induced a strong IFNγ response of epitope-specific CD4+ T cells, exemplary 
shown for pp65<245-263> specific CD4+ T cells (Figure 1B) (mean frequency ± S.D.: 34.6 ± 24.7 
%, n=5). 
  
 
 
 
 
 
 
 
 
 
Figure 1B. CMV Epitope-Specific CD4+ T cells Can Be Expanded In Vitro.  
Percentage of epitope-specific CD4+ T cells at day 14 of expansion, as demonstrated by 
intracellular IFNγ staining after TCR stimulation with autologous APC and the specific 
antigenic peptides or unspecific control. Data are representative of five independently 
expanded epitope-specific T-cell lines, exemplary shown for pp65<245-263> specific T cells. 
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Flowcytometric analysis on day 14 of epitope driven expansion determined different subsets 
regarding the CD25 expression levels – low, intermediate, and high. Intensity of CD25 
expression and frequency of CD4+CD25high T cells in the T-cell lines  (Figure 2A, left) 
(mean frequency ± S.D.: 4.5 ± 2.6 %, n=5) was comparable to those of natural 
CD4+CD25high Treg observed directly in peripheral blood (Baecher-Allan, et al., 2004). 
 
 
Figure 2A. Expanded Epitope-Specific CD4+ T cells Comprise Cells Possessing 
CD4+CD25high Treg Phenotype. 
Epitope-specific CD4+ T cells expanded over 14 days in vitro were sorted according to CD25 
expression. Numbers in dot plots indicate the percentage of gated CD4+CD25low (CD25low) 
and CD4+CD25high (CD25high) cells after sorting. Data are representative of five 
independent experiments. 
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Figure 2B. Expanded CD4+CD25high T Cells Express CD127low. 
Numbers in histograms indicate the percentage of CD127 expression on gated CD25high, 
CD25int and CD25low CD4+ T cells. Two representative data (specificity for IE1<89-107> or 
pp65<245-263>) of five independent expanded T-cell lines are shown. 
  
 
However, in conditions involving deliberate T cell activation CD25 is a poor indicator for 
human regulatory T cells. Thus, we additionally analyzed CD127 and correlated it with CD25 
expression. Conversely to CD25low and CD25intermediate CD4+ T cell populations, the 
CD4+CD25high T-cell subset expressed CD127low after specific re-stimulation (Figure 2B), 
indicating the presence of putative iTreg cells distinct from recently activated effector T cells 
(Seddiki, et al., 2006). 
 
 
2.2 CMV-SPECIFIC EXPANDED CD4+CD25HIGH ARE SUPPRESSIVE 
   
 We next asked whether these specifically expanded CD25high T cells do also bear 
regulatory capacity. Therefore, five independent CD4+ T-cell lines with distinct CMV-epitope 
specificities from the two immuno-dominant antigens (IE1, pp65) were expanded to sufficient 
CD4+CD25high cell numbers to perform functional analysis.  
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On day 14, CD4+CD25low (CD25low) and CD4+CD25high (CD25high) T cells were sorted 
to high purity (Figure 2A, right) and restimulated by their specific peptide or an unspecific 
control peptide. Notably, as depicted in Figure 3A and Figure 4A upon specific re-stimulation 
CD25low (CD127+) T cells produced high levels of IL-2, whereas IL-2 secretion in CD25high 
(CD127low) T cells was significantly lower (mean ± S.D.: 1,237.0 ± 340.1 compared to 122.5 
± 119.5 pg/ml, n=5, p=0.0001 t-test, two tailed). Furthermore, CD25low and CD25high T cells 
were co-cultured at different ratios 1:0, 1:1, 1:0.5, 1:0.1 and 0:1 for 24h in the presence of the 
indicated specific peptide and APC. Indeed, CD25high T cells suppressed the IL-2 secretion 
of CD25low T cells in a dose-dependent manner. 
 
 
 
Figure 3A. Suppression of Specific IL-2 Secretion by CD4+CD25high T Cells.  
Sorted CD4+CD25low (CD25low) and CD4+CD25high (CD25high) populations were 
subsequently co-cultured at different ratios in the presence of APC and the respective 
peptide. After 24 h, secretion of IL-2 was measured by flowcytometric bead array. Unspecific 
stimulation showed background cytokine release near or under limit of detection (data not 
shown). Two representative data (specificity for IE1<269-288> or pp65<245-263>) of four 
independent experiments are shown. 
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This regulatory function in vitro was not only established for CD25high cells with different 
CMV antigen and epitope specificity, exemplary presented for IE-1<269-288> and pp65<245-263> 
(Figure 3A) but also reproducible over time (>1yr), as three independently isolated and 
expanded CD25high T-cell lines from the same donor and of the same Ag-specificity to 
pp65<245-263> consistently possessed the ability to suppress IL-2 secretion (n=3, p=0.031, 
paired t-test, two tailed) (Figure 3B).  
 
 
 
Figure 3B. Stable Suppression of Epitope-Specific IL-2 secretion by CD25high Treg.  
CD25high T cells specific for pp65<245-263> isolated and expanded at three different time points 
stably suppressed IL-2 secretion of CD25low cells upon antigen-specific stimulation. IL-2 
secretion was measured by flow-cytometric bead array. Data are representative of two 
independent epitope specificities. 
 
 
Additionally, we found that peptide-driven proliferation of CD25low T cells in vitro (Figure 3C) 
was suppressed when they were co-cultivated with CD25high T cells recognizing the same 
epitope (n=3, p=0.003, paired t-test, two tailed). The inhibition on CD25low proliferation was 
also dose-dependent and even evident at a tenfold smaller proportion of CD25high cells.  
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Figure 3C. Suppression of Epitope-Specific Proliferation by CD25high Treg. 
Expanded CD25low T cells were cultured alone or together with CD25high T cells at different 
ratios over 5 days in the presence of APC and the indicated specific peptides. Cells that were 
dividing in the last 24h were measured by [3H] thymidine incorporation. Data are shown for 
three independent experiments with different epitope specificities (pp65<245-263>, pp65<25-39>, 
IE1<269-288>). 
 
 
On the basis of these evaluations, we assumed that expanded CD25high T cells suppress 
the proliferation and IL-2 secretion of CD4+CD25low T cells with the same antigen-specificity 
in a dose-dependent fashion. These findings are consistent with the defined in vitro 
properties of Treg cells in several previous reports (Lohr, et al., 2006), where the involvement 
of Treg cells in controlling immune responses to tissue transplants, tumors and various 
infectious agents (Sakaguchi, 2005) (Belkaid and Rouse, 2005) has been firmly established. 
These Treg cells are purported to use many cellular processes to control immune responses.  
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2.3 CD4+CD25HIGH Treg NEED SPECIFIC EPITOPE RECOGNITION FOR 
SUPPRESSIVE FUNCTION 
  
 It has been reported in mice, that once activated, Treg cells suppress in an antigen-
unspecific way called ´bystander suppression` (Tarbell, et al., 2007) (Qin, et al., 1993). To 
investigate this issue for the human CMV-specific iTreg cells in this study, we tested whether 
IE-1<269-288>CD25high iTreg cells can suppress the IL-2 response of pp65<245-263>CD25low 
non-regulatory memory T cells with a different
 
antigen specificity (Figure 3D). Importantly, 
both subsets were isolated and expanded from the same donor, and could thereby be 
restimulated in the presence of the same autologous APC.  
 
 
Figure 3D. Suppressive Capacity of CMV-Antigen Specific CD25high Treg Requires 
Activation by Their Cognate Epitope. 
CD25low and CD25high T-cell populations from the same donor but of different antigen-
specificity were cultured alone or co-cultured at a ratio of 1:1. The CD25high cells were 
cultured with (+) or without (-) their specific antigens (IE-1<269-288> or pp65<245-263>). IL-2 
secretion was measured by flow-cytometric bead array. Data are representative of two 
independent experiments. 
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For this purpose, we firstly confirmed IL-2 suppression of pp65<245-263>-specific CD25low non-
Tregs by pp65<245-263>-specific CD25high iTreg cells after re-stimulation with their respective 
peptide (pp65<245-263>) as established previously. Next, pp65<245-263>-specific CD25low cells 
were cultured together with CD25high iTregs specific for IE-1<269-288> (also tested to express 
respective peptide-specific suppressive function; data not shown) in presence of both 
cognate antigens, pp65<245-263> and IE-1<269-288>. Under this conditions, IL-2 secretion of 
pp65<245-263>-specific CD25low cells was also diminished, contributing to ´bystander 
suppression` of CD25high iTreg cells in vitro. However, this suppressive ability was lost, 
when IE-1<269-288>-specific CD25high iTreg cells did not see their respective specific antigen 
during this co-culture. 
Consequently, we demonstrated that although human CMV-specific CD25high iTreg cells 
can suppress antigen-unspecifically (bystander suppression), they require prior specific 
activation through their TCR, comparable to other models (Roncarolo, et al., 2001) (Levings, 
et al., 2005). 
 
 
2.4 CMV-SPECIFIC Treg EXPRESS LOW IL-2, HIGH IFNγ AND IL-10 
  
 Having shown that expanded foreign-antigen specific Treg cells can be isolated by 
CD25high expression correlating with suppressive function in vitro we sought to further 
characterize this population for phenotypic and functional characteristics reported particularly 
for iTreg. Following re-stimulation with peptide in vitro, comparable IFNγ release was 
observed in both CD25high and CD25low T cells (IFNγ: mean ± S.D.: 19.39 ± 7.01 pg 
x10e3/ml vs. 17.60 ± 8.74 pg x10e3/ml, respectively, n=5, p=0.730, t-test, two tailed). On the 
contrary, production of IL-10 was significantly higher in CD25high compared to CD25low T 
cells (IL-10: mean ± S.D.: 74.47 ± 42.49 pg/ml vs. 23.91 ± 9.69 pg/ml, respectively, n=5, 
p=0.031, t-test, two tailed) (Figure 4A, middle, right).  
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Figure 4A. Expanded CD25high Treg Cells Secrete Upon Epitope-Specific Stimulation 
Low IL-2, High IFNγ and IL-10. 
CD25low or CD25high T cells were stimulated specifically for 24h. Concentrations (pg/ml) of 
secreted IL-2, IL-10 or IFNγ were measured by flow-cytometric bead array. DMSO control 
showed a background near or under the limit of detection (data not shown). Data are mean ± 
S.D. of five independent epitope specific T-cell lines (t-test, tow-tailed). 
 
 
IL-10 has been considered to be the key trait of an iTreg subset, classified as CD4+ T-
regulatory type 1 (Tr1) cells. Upon activation via the TCR human Tr1 cells produce, besides 
IFNγ, high levels of IL-10 but very low levels of IL-2. They are described to suppress T-cell 
responses and maintain immunological tolerance (Levings, et al., 2005). 
Whilst the development and function of nTreg cells is correlated with Foxp3 expression, 
studies in humans proved that Tr1 cells do not constitutively express FOXP3 (Vieira, et al., 
2004) (Roncarolo and Gregori, 2008). Therefore, we were interested to provide details of 
FOXP3 expression status within IFNγ+ compared to IL10+ CD25high iTreg on single cell 
level (Figure 4B) and importantly to determine the FOXP3-expression stability in the human 
CMV-specific iTreg subset.  
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Figure 4B. FOXP3+ Expression in CD25high Treg Cells is Not Correlated with IL-10 and 
Inversely Correlated with high IFNγ Production.  
Expanded epitope-specific T cells were stimulated for 16h in the presence of autologous APC 
and the respective specific peptides. Brefeldin A was added to the culture after 2h of 
stimulation. IL-10, IFNγ and FOXP3 were measured by intracellular flowcytometry. Numbers 
in dot plots indicate the percentage of gated CD4+CD25high cells (CD25high). One 
representative data (specificity for pp65<245-263>) of four independent experiments are shown. 
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2.5 METHYLATED FOXP3-DNA STATUS SUGGESTS TRANSIENT FOXP3 
UPREGULATION IN CMV-INDUCED Treg CELLS 
 
 The total expression of FOXP3 on the different functional CD4+ subsets was 
determined by intracellular staining, and approximately 53% of CD25high and 29% of 
CD25low cells were FOXP3+ on day 14 of expansion. The gating strategy for FOXP3+ T 
cells and an exemplary dot plot is shown for IE1<269-288>-specific CD4+ T cells (Figure 5A). 
 
 
 
 
 
 
Figure 5A. FOXP3 Protein Expression Analyzed by Intracellular FACS Staining.  
Numbers in dot plots indicate the FOXP3+ percentage of gated CD25low or CD25high CD4+ 
cells. Isotype-control antibody showed background staining of less than 0.2% (data not 
shown). Data are representative for five independent experiments and are shown exemplary 
for IE1<269-288> specific T cells.  
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Figure 5B. CD25high Treg Cells Express More Intense FOXP3 than CD25low T Cells. 
FOXP3+ (%) of CD4+ cells (left) and mean fluorescence intensity (MFI) of intracellular 
FOXP3 staining among gated CD25low and CD25high T-cell populations. Data are mean ± 
S.D. of five independent experiments (t-test, tow-tailed). 
 
 
 
 
FOXP3 intensity and frequency was always higher in CD25high than in CD25low cells 
(FOXP3 [MFI] mean ± S.D.: 28.9 ± 3.74 compared to 15.6 ± 0.75, n=5, p=0.002 t-test, two-
tailed) (Figure 5B); FOXP3+ [%] mean ± S.D.: 36.6 ± 9.56 % compared to 18.1 ± 11.63 %, 
n=5, p=0.004 t-test, two-tailed), and the same was true for FOXP3 mRNA expression (Figure 
5C) (FOXP3 mRNA [units/HPRT] mean ± S.D.: 0.84 ± 0.27 compared to 0.17 ± 0.06, n=3, 
p=0.071 t-test, two-tailed). 
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Figure 5C. CD25high Treg Cells Express More FOXP3 mRNA Than CD25low T Cells. 
FOXP3 mRNA expression of sorted CD25low and CD25high T-cell populations was analyzed 
by real-time PCR and normalized to HPRT (house keeping gene). Data are mean ± S.D. of 
three independent experiments (t-test, tow-tailed). 
 
 
These findings prompted us to test whether intermediate expression level of FOXP3 in 
CD25high T cells during CMV peptide-specific expansion might simply represent a transient 
induction of FOXP3. To clarify this hypothesis we took advantage of a recent study in mice 
that has proven that a stable Foxp3 expression, as committed in the ex vivo isolated 
Foxp3+CD4+CD25+ Treg lineage must be epigenetically modified by complete 
demethylation of CpG motifs within an evolutionary conserved region on the foxp3 locus 
(Floess, et al., 2007). 
 
On the basis of this evaluation, we analyzed the methylation status of the homologous 
conserved CpG-rich region (Amplicon 5) on the human foxp3 locus (Baron, et al., 2007) in 
sorted CD25high iTreg cells and CD25low T cells on day 14 of expansion by bisulfite 
sequencing. Interestingly, no difference in the degree of methylation between CD25high and 
CD25low cells was observed. Both populations displayed incomplete foxp3-demethylation as 
illustrated for CD25high and CD25low samples from two independent expanded CD4+ T cell 
lines specific for the epitopes IE-1<269-288> and pp65<245-263>  (Figure 5D).  
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Figure 5D. Incomplete Demethylation of FOXP3-DNA Locus in Expanded CD25high 
iTreg and CD25low Teff Cells. 
DNA-methylation status of the human foxp3 amplicon 5 (Amp 5) is depicted. Data of two 
independent expanded epitope-specific (IE-1<269-288> or pp65<25-39>) CD4+ T cells from a 
female donor are shown. Data are representative for five individual donors (female and man). 
The upper panel depicts CD25high T cells and the lower CD25low T cells, separated by 
FACS Sort and tested for antigen-specificity and in vitro function, respectively. The selected 
amplicon is subdivided by horizontal boxes; each box represents methylation rate of a single 
CpG motif according to the colour code (yellow = 0% methylation, blue = 100% methylation). 
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This result corresponds to a recent finding that in vitro TGF-β induced Tregs in mice and also 
in humans display incomplete demethylation despite of suppressive activity and high Foxp3 
expression (Floess, et al., 2007) (Baron, et al., 2007). Upon withdraw of TGF-β during re-
stimulation these in vitro induced Tregs lost Foxp3 expression and correspondingly their 
suppressive activity. In contrast, human ex vivo freshly isolated polyclonal CD4+CD25high 
Treg cells but not naïve CD4+CD25- T cells comprise complete demethylation of CpG motifs 
as described previously (Baron, et al., 2007). 
In summary, our experiments verify that human in vitro expanded CMV-specific 
CD4+CD25high Treg cells are suppressive and contain a proportion of FOXP3 high 
expressing T cells. Furthermore, incomplete foxp3-demethylation status contributes to an 
antigen-induced transient FOXP3 upregulation in this CD25high iTreg population. 
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2.6 Treg AND TEFF CELLS ARE CLONALLY IDENTICAL IN VITRO 
  
 To analyze the clonal TCR-repertoire of iTreg and non-Treg cells, which respond to 
the same foreign epitope, we took advantage of a recently described approach to type TCR-
clones by highly sensitive analysis of Vβ-chain rearrangements and sequencing of CDR3 
hypermutation region (Wlodarski, et al., 2006) (Wlodarski, et al., 2006).  
When we assessed TCR repertoire within purified CD25high and CD25low T cell populations 
responding to the same CMV peptide, it became apparent that in all three independently 
expanded specific CD4+ T-cell populations single TCR Vβ-CDR3 clones were dominantly 
expanded, as reflected by their frequency; 25-50 % in CD25high and 5-63 % in CD25low T 
cells, respectively (Table 2). Importantly, both CD25high and CD25low populations shared 
the dominantly expanded TCR clone (Figure 6A), indicating that human CMV-peptide 
specific CD25high and CD25low cells are clonally identical. 
 
Tab. 2:  Frequency of Shared Dominant TCR Clones. 
 
Dominant TCR Vβ-CDR3 Clone Frequency 
Epitope Vβ CDR3 Jβ CD25low CD25high 
IE1<269-288> Vβ22 CASRGTGDQPQHF Jβ5.1 35 % 31 % 
pp65<25-39> Vβ14 CASSTTGETAFF Jβ1.4 5 % 50 % 
pp65<245-263> Vβ12 CAISESGMTVATNEKLFF Jβ1.1 63 % 25 % 
Vβ: variable region of the T-cell receptor (TCR) beta-chain; CDR3: complementary 
determining region 3 of the TCR beta-chain; Jβ: joining region of the TCR beta-chain 
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Figure 6A. Epitope-Specific CD25high Treg and CD25low Teff Cells Share Same 
Dominant Expanded TCR Clone. 
Sequence-overlap of dominant TCR in regulatory CD25high and non-regulatory CD25low T 
cells expanded antigen-specifically in vitro. Dominant TCR clones were calculated from the 
number of expanded TCR sequences (≥ 2) within all sequenced clones (16 ≥ 21) of a given 
population. Shown amino acid sequences represent complementary determining regions 3 
(CDR3) within the observed variable region of the TCR beta-chain (TCR Vβ). Observed 
frequency of most dominant TCR in CD25high and CD25low T cell subsets were 25% and 
63% of Vβ12-CDR3 in pp65<245-263> specific cells (Figure 6A, top) and 31% and 35% of Vb22-
CDR3 in IE-1<269-288> specific cells (Figure 6A, bottom), respectively. TCR clono-typing by 
Vβ-CDR3 sequencing was performed as described previously (Wlodarski, et al., 2006). Two 
exemplary data of three independent experiments are shown.  
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 To more directly assess a possible clonal identity between iTreg and non-Treg cells, 
expanded T cells specific for pp65<245-263> were sorted by flow cytometry for the dominant 
encountered Vβ12+ clone to high purity (Figure 6B). Subsequently, Vb12+ cells were 
separated according to their CD4+CD25high or CD4+CD25low phenotype (Figure 6C, top).  
 
   
   B 
 
 
Figure 6B. Single Vβ12-CDR3 T-cell clone is highly expressed in sorted pp65<245-263> 
specific Vβ12+ T cells. 
The single Vβ12-CDR3 T-cell clone was in Vβ12+ T cells 12-fold higher expressed compared 
to Vβ12- T cells. Expression was verified by Vβ12-CAISESGMTVATNEKLFF-Jβ1.1 clone-
specific real time PCR (Figure 6D) and normalized to CD3zeta (CD3). Data are 
representative of two experiments with independent specificities. 
 
 
In fact, Vβ12+CD25high T-cell clones suppressed the CMV peptide-dependent IL-2 secretion 
of clonally identical Vβ12+CD25low T cells (Figure 6C, bottom) upon in vitro co-cultivation. In 
other words, the same “mother” clone can differentiate into CMV peptide-specific cells 
expressing regulatory or non-regulatory functions. 
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Figure 6C. Epitope-Specific Expanded T Cells of the Same Clonality Are Capable of 
Regulatory and Effector Function.  
Top, Vβ12 expressing cells were sorted from in vitro expanded pp65<245-263> specific T cells 
by flow cytometry and subdivided in to Vβ12CD25low and Vβ12CD25high CD4+ T cells. 
Sorted populations were subsequently co-cultured at a ratio of 1:1 for 24 h in the presence of 
APC and the indicated specific peptides. 
Bottom, Vβ12CD25low secreted IL-2 in the presence of pp65<245-263>, whereas in absence 
(Control) IL-2 secretion was near the limit of detection (ND) and cultured together with 
Vβ12CD25high cells IL-2 secretion was suppressed. Data are representative of two 
experiments with independent T-cell clones of different specificity. 
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2.7 FRESHLY ISOLATED CD25HIGH AND CD25LOW CELLS SHARE SAME TCR 
CLONE 
 
 The observed incomplete FOXP3-demethylation might suggest that the CMV-
triggered CD25high iTreg isolated after expansion, are generated from CD25low non-Treg 
cells as seen for TGF-β induced Treg. To address this point, we screened freshly isolated 
CD4+CD25high and low subsets for the presence of the same T-cell clones detected in both 
subsets after CMV-specific in vitro expansion (see above). On the basis of the identified 
dominantly expanded TCR-Vβ CDR3 clones within the CMV-epitope specific CD25high 
population, we designed a TCR clonotype specific PCR (Figure 6D).  
 
 
Figure 6D. Design of TCR Clonotype Specific PCR. 
Real-time PCR is designed to employ CDR3-specific Taq-probe (Probe), Vβ-family specific 
forward primer (Fw) and Jβ-specific reverse primer (Rev). To increase the fidelity, each 
primer covered the flanking nucleotides of each CDR3 sequence. TCR: T-cell receptor; VB: 
variable region of the TCR β-chain; CDR3: complementary determining region 3 of the TCR 
β-chain; JB: joining region of the TCR β-chain 
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Figure 6E. Freshly Isolated CD25low and CD25high CD4+ Cells Contain The Same 
CMV-Epitope Specific T-cell Clone. 
Dominant expanded epitope-specific CD25high Treg clone was detectable in ex vivo isolated 
autologous peripheral CD4+CD25low and CD4+CD25high T-cell population by single Vβ-
CDR3 specific PCR. Top, in vitro expanded IE1<269-288> specific T cells (top left) and ex vivo 
isolated autologous PBMC (top right) were sorted according to CD25 expression. Bottom, 
TCR Vβ22-CDR3 clonotype specific real-time PCR. Relative expression of the Vβ22-CDR3 
T-cell clone in IE1<269-288> specific expanded CD25low, CD25high and the total T-cell line 
(bottom left) was found to be tenfold higher compared to directly ex vivo isolated CD25low, 
CD25high subsets and total PBMC (bottom right). In allogeneic PBMC of a CMV 
seronegative donor (Control) and also in expanded pp65-epitope specific T cells (Control) the 
Vβ22-CDR3 clone was not detectable (ND). Data are representative of two independent 
experiments. 
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First, we tested the established Vβ22-CDR3 PCR for specificity by using in vitro expanded 
IE1<269-288> T cells (Figure 6E, left). As expected we detected high expression of the 
dominantly expanded T-cell clone in the purified CD25high as well as CD25low T cells, and 
also in the total non-purified T-cell line pool. By contrast, in autologous expanded T cells of a 
different CMV-specificity (Control), the IE1<269-288> specific T-cell clone was not detectable. 
Moreover, PCR was sensitive enough to detect the Vβ22-CDR3 T-cell clone in the freshly 
isolated non-cultured autologous PBMC. As an additional negative control allogeneic PBMC 
from a CMV seronegative donor (Control) were used (Figure 6E, right). 
Most notably, the CMV IE1<269-288> specific T-cell clone was present in the both freshly 
isolated non-cultured CD4+CD25high and CD4+CD25low subsets of the autologous PBMC, 
implying that the in vitro confirmed clonal identity of Treg and non-Treg populations reflects 
the in vivo situation. Additionally, this experiment was also performed with a Vβ12-CDR3 
clonotype-specific PCR with equal results (data not shown). 
These data underline that the generation of CMV-specific iTreg does not arise by an in vitro 
culture artefact (conversion from CD25low) but occurs in vivo, likely as a result of chronic 
exposition to CMV.  
 
 
2.8 HIGH Treg FREQUENCY IN PATIENTS WITH RECURRING CMV REACTIVATIONS 
 
 If iTreg cells are generated from effector or memory CD4+ T cells continuously 
throughout life, persistent infections with viruses, such as CMV that induce large-scale 
differentiation of human memory T cells (Fletcher, et al., 2005) (Appay, et al., 2002) (Khan, et 
al., 2002), would be expected to also induce a disproportionate representation of CMV-
specific iTreg in the total Treg cell pool.  
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Such an imbalance might contribute to the CMV-related hyporesponsiveness as reported in 
some solid organ transplant (SOT) patients undergoing chronic immunosuppression (Reinke, 
et al., 1999). 
 
 
 
Figure 7A. Study Design. 
CMV seropositive transplant patients with Non-recurring or Recurring (Patient Cohorts) CMV-
activations are monitored for frequency and impact of Treg cells. CMV: Cytomegalovirus; Tx: 
Transplantation; yrs: years 
 
 
 
To investigate this issue, we monitored kidney transplant patients with or without recurring 
CMV outbreaks (Recurring vs. Non-recurring) (Figure 7A) not only for frequencies of 
CD25+FOXP3+ Treg cells in peripheral blood but also for the putative negative impact of 
CD25high Treg cells on CMV-antigen specific immune response. Characteristics of both 
patient cohorts are summarized in Table 3 (Methods).  
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In fact, patients with recurring CMV outbreaks displayed significantly higher CD25+FOXP3+ 
Treg frequencies compared to Non-recurring patients (CD25+FOXP3+ [of CD4+ %]: mean ± 
S.D., Recurring [n=11] and Non-recurring [n=8] 3.7 ± 1.06 and 2.4 ± 0.94, respectively, 
p=0.016 t-test, two-tailed) (Figure 7B).  
 
 
Figure 7B. Patients With Recurring CMV Outbreaks Display Higher Treg Frequency.  
Representative dot plot for staining characteristics and gating strategies of CD25+FOXP3+ 
Treg cells from CD4+ T cells in the peripheral blood is shown (Figure 7B, left). Isotype control 
staining for anti-FOXP3 showed a background of 0.5% or less. 
Frequency of CD25+FOXP3+ cells among CD4+ T cells is plotted (Figure 7B, right). Patients 
undergoing recurring CMV outbreaks (Recurring) show significant higher Treg frequency 
than patients with single CMV outbreak (Non-recurring). Data are mean ± S.D.: of Recurring 
[n=11], 3.7 ± 1.06 versus Non-recurring [n=8], 2.4 ± 0.94, p=0.016 (t-test, two-tailed). 
 
 
Additionally, CD4+CD25high T cells displayed significantly higher FOXP3 MFI in Recurring-
CMV patients (p=0.010 t-test, two-tailed) whereas the MFI of CD4+CD25intermediate T cells 
was comparable in the Recurring and Non-recurring cohort (not significant) (Figure 7C). 
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Figure 7C. CD4+CD25high but Not CD4+CD25int T Cells Show Significant Increased 
FOXP3 Intensity Within Recurring Patient Cohort. 
Mean Fluorescence Intensity (MFI) of FOXP3+ among CD4+CD25high T cells (Treg) and 
CD4+CD25intermediate (activated Teff) is plotted. Patients undergoing recurring CMV 
outbreaks (Recurring) show significant higher FOXP3 intensity of CD4+CD25high Treg cells 
than patients with single CMV outbreak (Non-recurring). Data are mean ± S.D.: of Recurring 
[n=11], versus Non-recurring [n=8], (t-test, two-tailed). 
 
 
2.9 HIGH SUPPRESSIVE IMPACT OF CD25HIGH Treg IN CHRONICALLY CMV-
INFECTED PATIENTS 
 
 To examine a possible involvement of peripheral iTreg cells on CMV-specific T cell 
response in these patients, we depleted CD25high T cells from patient’s PBMC in vitro 
before stimulation and functional analysis of CMV-specific non-Treg. We focused on 
CD25high T cells with regard to our previous observation that these cells comprise the 
majority of FOXP3 high cells and, moreover, because CMV-specific iTreg clones are present 
in freshly isolated CD25high T-cell populations. For selective CD25high Treg but not 
CD25intermediate depletion anti-CD25 magnetic beads were down titrated (Figure 8A).  
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Subsequently, PBMC and CD25high-depleted cells were incubated with CMV pp65 and IE1 
protein-spanning overlapping peptide pools which encode all possible epitope sequences 
and thereby provide HLA-type independent CMV-specific stimulation.  
 
 
 
Figure 8A. In-Vitro Depletion of CD25high Cells from PBMC of Recurring and Non-
Recurring CMV Patients. 
PBMC were isolated from peripheral blood samples donated from patients with Recurring or 
Non-recurring CMV reactivations, respectively. Selective depletion of CD25high cells by 
magnetic separation (α-CD25 beads 3µg/1x 10e7 cells) was performed. Numbers in dot plots 
indicate percentages of the gated CD4+CD25high cells. Resulting cell-subsets (PBMC and 
CD25high depleted, respectively) were subsequently stimulated with peptide pools of the 
CMV antigens (Ag) IE1 and pp65 for 24 h.  
 
Analysis showed that peptide-specific IL-2 and IFNγ cytokine release was considerably 
increased in Recurring-CMV patients after iTreg depletion (mean ± S.D.: n=6, IL-2 [fold-
change]: 6.6 ± 10.5; IFNγ [fold change]: 65.0 ± 129.2) (Figure 8B). Furthermore, Treg related 
cytokine suppression was correlated with the clinical status of infection history. Treg 
depletion led to six fold higher IL-2 and eight fold higher IFNγ increase in Recurring-CMV 
patients compared to Non-recurring patients (Data are mean ± S.D. of six and five 
experiments per cohort) (Figure 8B). 
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Figure 8B. Recurring CMV Patients Show Higher Regulatory Impact by CD25high Treg 
Cells On Antigen-Specific T-cell Response. 
Recurring-CMV patients displayed higher and more often increased CMV-antigen specific IL-
2 and IFNγ response after CD25high Treg depletion compared CMV Non-recurring patients.  
Cytokine release after 24h of stimulation with CMV IE1 and pp65 peptide pools was analyzed 
by flow-cytometric bead array. Fold change of IL-2 and IFNγ after CD25high depletion are 
plotted. Data are mean ± S.D. of six and five experiments per cohort (Recurring, Non-
recurring), respectively. 
 
 
These data demonstrate a higher frequency and a higher negative regulatory impact of 
CD4+CD25high Treg in patients who suffered from history of recurring CMV outbreaks and 
strengthen the hypothesis of a CMV-driven process of iTreg generation in vivo. 
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3 DISCUSSION 
  
 Our results show that human CMV-specific T-cell lines contain CD4+CD25high Treg 
cells that express IL-2low but IL-10high and exhibit incomplete foxp3 DNA demethylation. 
The CMV-specific Treg cells possess a phenotype of induced regulatory T cells with 
similarity to the recently described Tr-1 cells. Importantly, these CD25high Treg cells 
suppress CD25low Teff cells in an antigen specific fashion; and both subsets share the same 
dominantly expanded TCR clones. Moreover, the identical TCR clone could also be identified 
in freshly isolated CD4+CD25high and CD4+CD25low T-cell subsets suggesting the 
generation of CMV-specific Treg occurred already in vivo. Finally, the impact of iTreg on the 
CMV-specific T-cell response increases with recurring outbreaks of CMV compared to 
patients with non-recurring CMV activation. 
 
  
3.1 FOREIGN-ANTIGEN SPECIFIC Treg IN HUMAN CMV MODEL 
 
 The delicate balance between effector and regulatory T cells in vivo is critical in order 
to generate controlled host immune-response to pathogens, and an imbalance has been 
identified in many pathological situations (Belkaid and Rouse, 2005) (Vukmanovic-Stejic, et 
al., 2006) (Suvas, et al., 2003) (Suffia, et al., 2006) (Boettler, et al., 2005) (Rushbrook, et al., 
2005), particularly in chronic infections. As human Treg are difficult to clone only a few 
cognate epitopes of peripheral blood nTreg and iTreg cells have been described up to date 
(Walker, et al., 2005) (Ebinuma, et al., 2008). In addition, although peripheral Treg induced 
by foreign antigens, such as viruses resemble phenotypical and functional aspects of thymic-
derived nTreg, studies for their suppressive stability, including epigenetic modification of the 
foxp3 locus and clonal TCR diversity remained to be elucidated (Sakaguchi and Powrie, 
2007). 
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To address these questions we used the model of human CMV infection as the life-long 
persistence of the virus should support the clonal expansion not only of effector T cells but 
also of iTreg that might generate a clonal size allowing the analysis on clonal level. After 
specific stimulation of CD4+ T cells recognizing epitopes within the major CMV target 
antigens, pp65 and IE-1, our data have shown that in parallel to the memory effector T cells 
(expressing CD25 low - intermediate and CD127high, and the phenotype IL-2high IFNγhigh 
IL-10low) iTreg (expressing CD25high CD127low, and the phenotype IL-2low IFNγhigh IL-
10high) could be expanded. CMV-specific CD4+CD25high T cells clonally expanded in 
parallel to CD4+ effector T cells in vitro, gain suppressive activity on their CD4+CD25low 
non-Treg counterparts as consequence of specific recognition by their respective target 
antigen. In contrast to nTreg, iTreg express an incomplete FOXP3-demethylation pattern that 
is reflected by an intermediate FOXP3 protein and mRNA expression. 
 
 
3.2 HUMAN VIRAL-SPECIFIC TEFF AND Treg ARE CLONALLY IDENTICAL 
 
 Remarkably, we showed that in vitro expanded CD4+CD25high iTreg and 
CD4+CD25low non-Treg responding to the same foreign CMV epitope, share the dominantly 
expanded TCR defined by its unique Vβ-CDR3 sequence. Furthermore, we noted that this 
immuno-dominant TCR clone is capable to possess the phenotype and function of iTreg and 
non-Treg cells after specific expansion and TCR activation in vitro. Moreover, ex vivo 
CD4+CD25high Treg and CD4+CD25- conventional non-Treg freshly isolated from 
autologous peripheral blood comprised T-cell clones expressing the respective TCR with 
high affinity to the same CMV-epitope.  
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Thus, T-cell clones that recognize a specific foreign epitope dominantly expanded in Treg as 
non-Treg effector populations after specific triggering in vitro are already present in both 
peripheral CD4+CD25high and CD4+CD25low T-cell pools in vivo and do not result of an in 
vitro artefact.  
In summary, for our knowledge we could directly demonstrate for the first time that human 
virus-specific Treg and Teff induced by foreign antigens in vivo and in vitro are clonally 
identical. Additionally, our data suggest that iTreg gain higher influence on the response of 
conventional non-Treg following chronically repetitive antigen exposition in vivo, as shown by 
the dramatically enhanced cytokine secretion of conventional CMV-specific non-Treg from 
immuno-suppressed transplant patients with chronic active CMV infection after in-vitro 
depletion of CD25high iTreg. 
 
3.3 IMPLICATION FOR ADOPTIVE ANTI-VIRAL THERAPY 
  
 The ability to analyze the clonal repertoire of immunosuppressive Treg clones with 
specificity for defined antigens, as shown in this study, represents an improvement over 
published experiments, relying on TCR-analysis of polyclonal peripheral Treg cells with 
unknown antigen-specificity (Fujishima, et al., 2005) (Kasow, et al., 2004) (Scheinberg, et al., 
2007). Future comparative characterization of the specifically activated effector and 
regulatory T-cell clones promise to enable a ‘fine-tuning’ of antigen-specific T-cell transfer in 
various settings, such as adoptive therapy in patients suffering from Adenovirus, Hepatitis C 
virus, Epstein-Barr Virus or Cytomegalovirus related diseases, and thus is of considerable 
clinical importance. 
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3.4 POSSIBLE CO-EVOLUTION OF TEFF AND Treg IN VITRO AND IN VIVO? 
 
 Our observations suggest that peripheral iTreg cells can be generated not only in vitro 
but also in vivo, to exert suppressive function when exposed to relevant antigens and thus 
are suited for controlling inflammatory response to chronic infections, such as caused by 
CMV.  
These data do not answer the question whether the antigen-specific CD4+CD25high iTreg 
result by conversion from CD4+CD25low effector or memory T cells (Figure 9A, Sequential 
Model) as suggested in in vivo studies in TCR transgenic mice (Knoechel, et al., 2005) and in 
vitro studies in humans (Walker, et al., 2005). Alternatively, it is possible that the shared 
specificity and clonal identity of peripheral Treg with Teff cells is due to parallel development 
from naïve peripheral blood T cells exposed to the foreign antigen after infection (Figure 9A, 
Parallel Model) or rely on inherent cross-reactivity of naturally occurring Treg cells.  
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Figure 9A. Parallel Model and Sequential Model.  
Putative peripheral Treg-development models from the same naive “mother-clone” are 
illustrated as comic. Ag: Antigen; TCR: T-cell Receptor; Teff: effector T-cell clone; Treg: 
regulatory T-cell cone. 
 
  
Indeed, in humans it is not yet established whether foreign-antigen iTreg display similar TCR 
repertoires to those of nTreg. The total repertoire of nTreg cells is apparently more skewed to 
recognizing self-antigens (Hsieh, et al., 2004) (Figure 9B, Separate Model), although it has 
been described that they are able to perceive a broad repertoire of self- and nonself-antigens 
including pathogens (Belkaid and Rouse, 2005). Interestingly, a recently published report in 
mice has shown that thymically derived Foxp3+ Treg recognize foreign antigenic peptides as 
often as non-regulatory T cells (Pacholczyk, et al., 2007). 
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Figure 9B. Separate Lineage Model. 
Treg-development model in the thymus, resulting in self-antigen specific Treg lineage with 
clonal TCR-repertoire separate from foreign-antigen T-effector lineage induced in the 
periphery. Foreign-antigen recognition by Treg cells would rely on inherent TCR cross-
reactivity. Ag: Antigen; TCR: T-cell Receptor; Teff: effector T-cell clone; Treg: regulatory T-cell 
cone. 
 
 
3.5 FIRST DIRECT VERIFICATION OF ANTIGEN-SPECIFIC SINGLE Treg CLONE IN 
HUMAN INFECTION 
 
 So far, only a few antigen-specific Treg populations have been directly pictured in 
humans. These elegant approaches correlated suppressive activation in expanded CD25+ T 
cells (Walker, et al., 2005) or FOXP3 expression (Ebinuma, et al., 2008) with MHC-class II 
tetramer staining. Although, tetramer-positive CD4+ T cells discern the same antigen, they 
still constitute an oligoclonal population.  Hence, by using TCR-Vβ CDR3 clonotype-specific 
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PCR our data provide the first direct verification of single antigen-specific Treg clones in 
human infection to our knowledge. 
The CDR3 of the TCR-Vβ-chain is, due to the NDN modification the most diverse region of 
the αβ-TCR (Davis and Bjorkman, 1988); furthermore it is highly unique for each T-cell clone 
and most directly engages the antigenic peptide presented within the HLA groove of an 
antigen presenting cell (Borg, et al., 2005). Importantly, the TCR α-chain is not suitable for 
detection of αβ-T cell clonality as up to 30% of rearranged human peripheral blood T cells 
(Padovan, et al., 1993) and most human thymic and peripheral-blood CD4+CD25high+ Treg 
(Tuovinen, et al., 2006) can express a dual TCR with two distinct α-chains but only one β-
chain. Again, clonal TCR-Vβ CDR3 identity of CD25high Treg and CD25low non-Treg 
expressing the same TCR specific for a foreign-antigen strongly supports the idea of antigen-
related co-evolution between Tregs and effector or memory T cells in humans. 
 
 
3.6 CORELLATION OF Treg FREQUENCY AND SPECIFIC SUPPRESSION WITH CMV-
INFECTION STATUS IN VIVO 
  
 If that assumption is correct, then persistent infections such as CMV that are mainly 
controlled by T-cell immune response, would be expected to also induce a high proportion of 
CMV-specific regulatory T cells in the total Treg-cell pool. 
To address this hypothesis in biologically relevant conditions we monitored the involvement 
of Treg cells in transplanted patients undergoing recurrent CMV-reactivations, in comparison 
to patients with no or only one episode of CMV antigenemia. The latter situation is 
associated with increasing frequencies of conventional CMV-specific Th1 cells over time 
(Bunde, et al., 2005). In fact, patients with recurrent active CMV infections compared to 
control groups showed higher frequency of CD25+FOXP3+ Treg within the peripheral CD4+ 
T cells and a dramatic increase of Teff function after depletion of the former. These findings 
support our hypothesis of antigen-exposure driven iTreg expansion. 
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We envisage an imbalance of iTreg and effector T cells containing clonally identical T cells 
that can be activated by the same CMV epitope in acute phase of viral infection, as 
demonstrated in this study, may interfere with specific CMV response and clearance and 
thereby permit repeated viral outbreaks.  
 
 
3.7 FOXP3 STATUS IN SUPPRESSIVE ACTIVE FOREIGN-ANTIGEN INDUCED 
HUMAN Treg 
 
 Here we asked if the phenotype of the studied iTreg is stable? As we could easily 
reproduce the generation of iTreg recognizing the same epitope specificity from the same 
donor/patient even >1 year after the initial analysis, the phenomenon seems to be quite 
robust. Along with, the cells could be sorted at different time points of the expansion culture 
without significant functional differences. The durable absence of CD127 expression (in 
contrast to the CD25low and intermediate subsets) further supports the Treg stability. 
Published reports have shown that stable Foxp3 expression, going along with demethylation 
of a CpG-rich region on the foxp3 locus is critical for the lineage stability and suppressive 
function in nTreg (Floess, et al., 2007). To examine if foreign-antigen specific iTreg also 
require epigenetic modification of foxp3, we analyzed in CD4+CD25high and CD4+CD25low 
T cells expanded in vitro after induction by their cognate epitope. Interestingly, both 
populations the CD25high Treg cells and the CD25low effector T cells of five separate 
donors exhibit almost no demethylation in this CpG-rich foxp3 region, although the 
suppressive CD25high cells comprised significantly more FOXP3 high T cells compared to 
CD25low cells. Consequently, the partial FOXP3high expression concurrently with 
methylated foxp3 status depicted in suppressive antigen-specific CD25high population in 
vitro suggests a transient FOXP3 upregulation.  
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This argues along with possibility of Treg conversion (Figure 9A, Sequential Model) from 
antigen-induced effector T cells in vitro or in vivo. Additionally, human Tr1-like Treg cells 
display a similar FOXP3 pattern (Roncarolo and Gregori, 2008). 
The mechanism of action by iTreg is less clear. We could demonstrate the need for prior 
antigen-specific stimulation of iTreg to exhibit their suppressive activity. Once activated, 
however, the iTreg are able to suppress not only effector T cells of the same but also of 
distinct specificity. Regarding their regarding their phenotype (CD4+CD25high IL-2low 
IFNγhigh IL-10high) and their FOXP3 regulation (FOXP3 intermediate, incomplete FOXP3-
demethylation) the studied iTreg population express similarities to the recently described Tr1 
cell subset (Levings, et al., 2005) (Roncarolo and Gregori, 2008). As recent reports suggest 
that FOXP3 does not correlate with suppressor function in human Tr1; furthermore FOXP3-
independent mechanisms, mediated by IL-10, contribute to the induction and suppressor 
function of these iTreg (Roncarolo and Gregori, 2008), we wondered whether IL-10 might 
mediate the observed suppressive effects. Preliminary data, however, suggest that IL-10 
neutralization does not prevent the suppressive function of CMV-specific iTreg. 
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3.8 CONCLUSIONS AND OUTLOOK 
  
 Taken together, our data support the impact of iTreg on the quality of virus-specific T-
cell response and the effective control of viral infection. Moreover, we suggest that exploring 
the proliferative capacity and suppressive activity as well as differential expressed molecules 
on these CMV antigen-specific Treg clones, could impart strategies to expand antigen-
specific effector T cells while inhibiting the activation and expansion of regulatory T cells.  
This might strengthen or re-establish the immune response in immuno-compromised 
patients, such as organ-transplanted patients often suffering from chronic viral disease, by 
highly specific adoptive T-cell transfer.  
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4 MATERIALS AND METHODS 
 
4.1 SUBJECTS 
 
 After informed consent, blood samples were collected from randomly selected kidney 
transplant patients and healthy subjects on the basis of CMV-IgG seropositivity, clinical 
course of CMV infection and HLA-class II type. The institutional review board of the Charité 
University Medicine, Berlin, approved the study. Transplant patients (>1 yr post-Tx) without 
actual signs of active CMV infection, and mostly on triple drug maintenance 
immunosuppression were recruited from the transplant outpatients unit.  
They were separated into two subsets: those patients with recurring CMV activations 
(Recurring) showed at least 2 positive CMV-antigenemia tests during >2 years follow-up 
before the study, despite adequate antiviral therapy; and those patients who had no or only 
one CMV-antigenemia (Non-recurring) during 2-6 years prior follow-up. Mean age of 
“Recurring” and “Non-recurring” was 51.1 and 54.4 years, respectively. Patients showed a 
current stable graft function and no other clinical complications. Patient characteristics are 
shown in the following Table 3. 
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Tab. 3: Characteristics of Monitored CMV Seropositive Patients. 
Patient Gender Age 
Maintenance 
Immunosuppression 
Post TX 
Highest 
CMV-Ag 
(x/10,000) 
History of 
CMV-antigenemia 
(Times*) 
 
R1 Male 43 Triple therapy 8.95 2 
R2 Male 57 CNI, steroid 2.18 2 
R3 Female 56 Triple therapy 10.80 3 
R4 Male 69 CNI, steroid 9.60 3 
R5 Male 48 CNI, steroid 5.45 4 
R6 Male 52 Triple therapy 6.29 4 
R7 Female 51 CNI, steroid 3.33 3 
R8 Male 40 CNI, steroid 32.00 2 
R9 Male 42 CNI, steroid 62.30 5 
R10 Male 64 CNI, steroid 3.5 5 
R11 Female 40 CNI, steroid 7.64 4 
N1 Male 73 Triple therapy 1.87 1 
N2 Female 47 Triple therapy 1.29 1 
N3 Male 33 Triple therapy 7.00 1 
N4 Female 43 Triple therapy 0.91 0 
N5 Male 40 Triple therapy 0.00 0 
N6 Male 57 CNI, steroid 0.54 0 
N7 Female 69 Triple therapy 0.00 0 
N8 Male 73 Triple therapy 0.00 0 
CMV: Cytomegalovirus; R: Recurring CMV activations (≥ 2 within > 2 years follow up); N: 
Non-recurring CMV activation (≤ 1); TX: kidney transplantation; CNI: calcineurin inhibitors; 
Triple therapy: application of CNI, mycophenolatmofetil and steroid; CMV-Ag positive: 
immunocytological CMV-antigenemia test with ≥ 1/10,000 positive cells; Times*: per year one 
positive test was enumerated. 
 
 
4.2 EXPANSION OF CMV-ANTIGEN SPECIFIC CD4+ T CELLS 
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4.2.1 CD4+ T-CELL EPITOPE MAPPING 
 
 Epitope mapping was conducted in accordance to the protocol published by our 
group previously (Kern, et al., 1998) and several MHC-class II restricted CMV epitopes were 
identified. Sequences of CD4-epitopes and considered presenting HLA-DR molecules are 
listed in the Table 1 (Results).  
In brief, CD4+ T-cell epitope mapping was based on the previously described ex vivo IFNγ 
induction assay (Hammer, et al., 2005) (Kern, et al., 1998) using crossover pools of pp65 an 
IE1 peptides. Single peptides consist of 15-amino acid (AA) each. Peptide pools comprise 
15-AA peptides (11 overlaps), spanning the total CMV pp65 or IE1 protein, respectively. 
Quality control included mass spectroscopy and HPLC (purity >70 %). Purified peptides were 
purchased from JPT Peptide Technologies, Berlin, Germany. 
Firstly, PBMC (2 x 106) of CMV seropositive donors were stimulated for 6 h with crossover 
peptide pools (final concentration of each peptide 1 µg/mL). Un-stimulated control sample 
was run in parallel (DMSO). Then, Brefeldin A (4 µg/mL) was added after 2h of culture and at 
6 h, cells were washed twice with ice-cold PBS. Next, cells were stained for surface markers 
(CD3+, CD4+ and CD8+) and finally intracellular FACS-stained for IFNγ production. Per 
sample, 150,000-250,000 events in the FSC/SSC lymphocyte gate were acquired on a FACS 
Calibur cytometer (Becton Dickinson). For data analysis CD3+ events were displayed in a 
CD8+ or CD4+ versus IFNγ+ dot plot. CD8+IFNγ+ or CD4+IFNγ+ cells were expressed as 
percent of the respective reference population. Un-specifically positive events in the 
corresponding regions in control samples were substracted. All identified epitopes were 
confirmed using individual peptides for stimulation.  
In this study, peptides coding for identified CMV CD4-epitopes pp65<25-39>, pp65<45-59>, 
pp65<245-263>, IE1<89-107> and IE1<269-288> were used for specific stimulation, subsequent 
isolation and CD4+ T-cell expansion.  
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4.2.2 ISOLATION AND EXPANSION OF SPECIFIC CD4+ CELLS 
  
 Human PBMC were stimulated for 6 hours with CMV peptides (1 µg/mL), which were 
identified as CD4-epitopes on pp65 and IE1 by epitope mapping as described above. 
IFNγ secreting cells, isolated by magnetic cell sorting (IFNγ secretion assay; Miltenyi Biotech) 
were expanded for 14 days with irradiated peptide-loaded autologous PBMC and rIL-2 (100 
U/ml) (Chiron Behring). During expansion T cells were cultured in complete medium (RPMI 
1640-stable glutamine, 10% FCS, 100 U/ml penicillin and 100 µg/mL streptomycin). 
 
 
4.3 FLOW-CYTOMETRY ANALYSIS 
 
 Monoclonal antibodies to CD3 (UCHT1), CD4 (RPA-T4), CD25 (M-A251), CD127 
(eBRDR5), IL-10 (JES3-19F1) and IFNγ (B27) and were purchased by Becton Dickinson and 
monoclonal antibodies to TCR-Vβ22 (IMU-546) and TCR-Vβ12 (VER2.32.1) by Beckman 
Coulter. FACS staining was performed according to the manufacturer’s protocols. 
CytomationSummit (MoFlow) and FlowJo (Tree Star) software were used for analysis. 
 
 
 
 
 
4.3.1 INTRACELLULAR FACS STAINING 
  
 For intracellular cytokine staining, cells were stimulated with CMV or control peptide 
for 6 hours (IFNγ analysis) or 16 hours (IL-10 analysis), respectively. Brefeldin A (4 µg/ml; 
Sigma-Aldrich) was added after 2 hours. Subsequent surface staining, the cells were then 
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fixed and permeabilized (Becton Dickinson) before staining for the cytokines IFNγ or IL-10. 
Short-term re-stimulation and subsequent intracellular cytokine staining were performed as 
described previously (Hammer, et al., 2005).  
For analysis of FOXP3 expression at single cell level, cells were first stained for the 
respective surface molecules and, after fixation and permeabilization (eBioscience), were 
incubated with FITC-conjugated monoclonal antibody PCH101 (anti-human FOXP3; 
eBioscience) or the IgG2a isotype control (eBR2a) based on the manufacturer’s 
recommendations. 
 
 
4.3.2 FACS-SORTING 
  
 T-cell lines and peripheral blood mononuclear cells (PBMC) were stained with 
appropriate antibodies. CD4+CD25low (CD25low), CD4+CD25high (CD25high) cells, as well 
as Vβ12+, Vβ12-, Vβ22+, Vβ22-, Vβ12CD25low, Vβ12CD25high, Vβ22CD25low and 
Vβ22CD25high CD4+ cells were sorted to high purity (92-99%) with DIVA cell sorter (Becton 
Dickinson). The sorting strategy included each time gating for CD3+ cells and excluded dead 
cells by gating of forward and side scatter. 
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4.4 FUNCTIONAL IN-VITRO ASSAYS 
 
4.4.1 ANTIGEN PRESENTATION AND CO-CULTURE 
  
 For re-stimulation cells were incubated for 24 h with 5 x104 or 2 x104 irradiated 
autologous lymphoblastoid B cells (Amrolia, et al., 2003), serving as antigen-presenting cells 
(APC), which were loaded with the respective specific CMV peptides (1 µg/mL) or control 
peptides (unspecific CMV-epitope or HCV-NS3<1027-1041>). 
FACS sorted CD25low and CD25high (5 x104) T cells from independent expanded T-cell 
lines were specifically re-stimulated and co-cultivated for 24 hours or 5 days at different 
ratios (1:0, 1:1, 1:0.5, 1:0.1 and 0:1), for analysis of cytokine release or quantification of 
proliferating cells, respectively. Vβ12CD25low and Vβ12CD25high (2 x104) T cells were 
purified from pp65<245-263> antigen-specifically expanded T cells by additional staining with the 
clonotypic TCR-Vβ12 antibody. IE1<269-288> specific T-cell lines were additionally stained with 
TCR-Vβ22 antibody to sort for dominant expanded T-cell clones. Cell culture was performed 
in complete RPMI medium at 37°C. 
 
 
4.4.2 CYTOKINE RELEASE AND PROLIFERATION 
  
 Supernatants were collected for quantification of IL-2, IL-10 and IFNγ release by 
cytometric bead array (CBA Kit; Becton Dickinson) based on the manufacturer’s protocol. For 
assessment of proliferation, co-cultivation was extended to 5 days with added rIL-2 (100 
U/ml, Proleukin). Cells dividing within the last 24 h were detected by [3H] thymidine 
incorporation. 
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4.5 FOXP3-DNA METHYLATION ANALYSIS 
  
4.5.1 DNA PREPARATION AND BISULFITE CONVERSION 
  
 DNA methylation analysis was performed by bisulfite sequencing as described 
previously (Baron, et al., 2007). Genomic DNA was isolated using the DNeasy tissue kit 
(Qiagen) following the manufacturer’s protocol for cultured human cells. Bisulfite treatment of 
genomic DNA was performed according to (Olek, et al., 1996), with minor modifications, 
resulting in the deamination of unmethylated cytosines to uracil, whereas methylated 
cytosines remain unchanged. In a subsequent PCR amplification, uracils were replicated as 
thymidines. Thus detection of a “C” in sequencing reactions reflects methylation of the 
genomic DNA at that site. Detection of a “T” at the same site reflects instead the absence of 
a methyl modification of the genomic cytosine CpG Motifs and transcription factor binding 
sites within differentially methylated, conserved element of the foxp3 locus. 
 
 
4.5.2 FOXP3 PCR AND SEQUENCING 
  
 PCR was performed in a final volume of 25 µL containing 1x PCR Buffer, 1 U Taq 
DNA polymerase (Qiagen), 200 µM dNTP, 12.5 pmol each of forward and reverse primers, 
and 7 ng bisulfite-treated genomic DNA at 95°C for 15 min, and 40 cycles of 95°C for 1 min, 
55°C for 45 s and 72°C for 1 min, and a final extension step of 10 min at 72°C. PCR products 
were purified using ExoSAP-IT (USB Corp.) and sequenced applying the PCR primers and 
the ABI Big Dye Terminator v1.1-chemistry (Applied Biosystems) followed by capillary 
electrophoresis on an ABI 3100 genetic analyzer. Sequences of primers used for bisulfite-
specific PCR and sequence reactions were previously described (Baron, et al., 2007). 
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4.6 TCR Vβ-CDR3 TYPING 
  
 TCR Vβ-CDR3 typing was performed by sequencing as described previously 
(Wlodarski, et al., 2006). In brief, CDR3 sequences of TCR Vβ-chain were amplified on 
cDNA samples using a multiplex PCR (BIOMED2) that covers all Vβ TCR gene 
rearrangements (van Dongen, et al., 2003). PCR product was ligated into TA cloning vector 
pCR2.1 (Invitrogen), heat-shock transformed into TOP10F E.coli and plated on X-gal-
covered agarose. Colony PCR and subsequent sequencing of positive colonies were 
performed as described previously (Wlodarski, et al., 2006). The frequency of an expanded 
clonotype was calculated as percentage of the particular unique clonotype out of the total 
number of sequenced Vβ-CDR3 regions. Sequences were analyzed using the 
ImMunoGeneTics information system TCR alignment tool (http://imgt.cines.fr). 
 
 
4.7 QUANTITATIVE REAL-TIME PCR 
 
4.7.1 RNA ISOLATION AND cDNA AMPLIFICATION 
  
 Total RNA from sorted cells was purified (Miniprep Kit; Stratagene) and a reverse 
transcription Kit (Ambion) was used for transcription into cDNA. The mRNA expression of 
human FOXP3, HPRT and CD3zeta were analyzed by quantitative RT-PCR. Sequences of 
primers (Metabion) and probes (Eurogentec) employed for quantitative RT-PCR are 
summarized under Table 4. Quantitative RT-PCR was performed as described previously 
(Kotsch, et al., 2004) in an Applied Biosystems 7500 using the following thermal protocol: 2 
min at 50 °C, 10 min at 95 °C, 15 s at 95 °C, 60 s at 60 °C. 
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4.7.2 DESIGN OF TCR CLONOTYPE-SPECIFIC PCR 
  
 Sequence derived from dominantly expanded clones in antigen-specific CD25high 
and CD25low T-cell subsets were used to design a TCR clonotype-specific PCR, employing 
CDR3-specific Taq-probe, Vβ-family specific forward primer and Jβ-specific reverse primer. 
To increase the fidelity, each primer covered the flanking nucleic acids of each CDR3 
sequence. In parallel, CD3zeta gene expression was analyzed. Quantitative RT PCR was 
performed as described (Kotsch, et al., 2004). Sequences of primers and probes 
(Eurogentec) are shown in the Table 4. 
     
 
55
55
  
4.7.3 PRIMERS AND PROBES 
 
Probes Sequence 
HPRT TTTCACCAGCTTGCGACCTTGA 
CD3zeta TGAGAGTGAAGTTCAGCAGGAGCGCA 
FOXP3 ACTTCCTCAAGCACTGCCAGGCGG 
IE1<269-288>Vβ22-CDR3 AGGACTCCATTCTGTCCAGC 
pp65<245-263>Vβ12-CDR3 ACTGTCATCCCACTCTCACTGATGGCAC 
Primers Sequence 
HPRT 
FW: AGTCTGGCTTATATCCAATTCG 
RW: GACTTTGCTTTCCTTGGTCAGG 
CD3zeta 
FW: TGCTGGATGGAATCCTCTTCAT 
RW: GGTTCTGGCCCTGCTGGTA 
FOXP3 
FW: AAGTGGCCCGGATGTGAGA 
RW: CATTGTGCCCTGCCCTTCT 
IE1<269-288>Vβ22-CDR3 
FW: GAAAGGCCTGATGGATCAAA 
RW: TCGAGTCCCATCCAAAAT 
pp65<245-263>Vβ12-CDR3 
FW: GACAGAGAGCTGGGTTCCACT 
RW: TCACTCTGGAGTCCGCTACCA 
 
 
Table 4. Primers and Probes.  
FW: forward primer; RW: reverse primer. Sequences are shown in the 5’ - 3’ direction. 
HPRT: Hypoxanthine-guanine phosphoribosyltransferase; FOXP3: human Fork head box 3; 
IE1: Immediate early protein 1; pp65: Phospho-protein 1; Vβ: T-cell receptor variable β chain, 
CDR3: complementary determining region 3. 
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4.8 IN-VITRO CD25HIGH-Treg DEPLETION 
  
 To deplete selectively CD25high but not CD25intermediate cells from PBMC, anti-
CD25 beads (Miltenyi Biotech) were down titrated to 3 µL per 1x 107 cells for magnetic 
separation. PBMC and CD25high-depleted cells were subsequently cultured in complete 
RPMI medium and stimulated for 24 h HLA-type independently with protein-spanning peptide 
pools (15-amino acid peptides with 11mer overlaps) of CMV pp65 and IE1 (JPT Peptide 
Technologies).  
 
 
4.9 STATISTICAL ANALYSIS 
  
 Mean values, S.D. values and Student’s t-tests (paired and unpaired) were calculated 
with GraphPad Prism (GraphPad Software). 
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